The 38 references in paper V. Yakushev I., M. Pokrovsky V., E. Beskhmelnitsyna A., O. Myasishcheva V., A. Litvinova S., I. Krivoshapova I., S. Demchenko A., В. Якушев И., М. Покровский В., Е. Бесхмельницына А., О. Мясищева В., А. Литвинова С., И. Кривошапова И., С. Демченко А. (2018) “Аргиназа II - новая мишень для создания эндотелиопротекторов // Arginase II - a new target in the development of endothelium protectors” / spz:neicon:vedomostincesmp:y:2015:i:1:p:26-30

1
Babko AV, Pokrovsky MV, Terehova EG, et al. Effect of combined application of arginase inhibitor L-norvaline and the fixed combination of losartan and hydrochlorothiazide in one tablet on endothelial dysfunction in experimental L-NAME-induced deficiency of nitric oxide method modeling. Kuban Research Medical Journal 2011; (4): 24–28 (in Russian).
(check this in PDF content)
2
Bokarev IN. Is arterial hypertension disease or risk factor? Clinical medicine 2004; (9): 69–71 (in Russian).
(check this in PDF content)
3
Pokrovskaya TG, Kochkarov VI, Pokrovsky MV, et al. The use of L-arginine for the prevention of endothelial dysfunction in inhibiting endothelial and inducible NO-synthase. Allergology and Immunology 2008; 9(3): 328 (in Russian).
(check this in PDF content)
4
Pokrovskaya TG. The role of pharmacological correction of L-arginine / NO pathway for modeling deficit of nitric oxide. Kuban Research Medical Journal 2008; (4): 122–125 (in Russian).
(check this in PDF content)
5
Pokrovskaya TG, Kochkarov VI, Danilenko LM, et al. Endothelial protective effect of L-arginine in pharmacological deficiency of nitric oxide method R E F E R E N C E S ния дефицита оксида азота. Научные ведомости Белгородского гос. ун-та 2006; 3(23): 43–51.
(check this in PDF content)
6
Покровский МВ, Покровская ТГ, Кочкаров ВИ, Артюшкова ЕБ. Эндотелиопротективные эффекты L-аргинина при экспериментальном моделировании дефицита оксида азота. Экспериментальная и клиническая фармакология 2008; 71(2): 29–31.
(check this in PDF content)
7
Солонин ДЛ, Сыренский АВ, Галагудза ММ и др. Роль оксида азота в регуляции растяжимости артериальных сосудов у нормо- и гипертензивных крыс. Артериальная гипертензия 2002; (6): 57–64.
(check this in PDF content)
8
Цепелева СА, Покровский МВ, Покровская ТГ. Кардио- и эндотелиопротективные эффекты ингибитора аргиназы L-норвалина при моделировании L-NAME-индуцированного дефицита оксида азота. Кубанский научный медицинский вестник 2011; (4): 185–87.
(check this in PDF content)
9
Berkowitz D, White R, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003; (108): 2000–2006.
(check this in PDF content)
10
Bivalacqua T, Hellstrom W, Kadowitz P, et al. Increased expression of arginase II in human diabetic corpus cavernosum in diabetic-associated erectile dysfunction. Biochem Biophys Res Commun. 2001; (283): 923–27.
(check this in PDF content)
11
Böger RH. The pharmacodynamics of L-arginine. J Nutr. 2007; (137): 1650–55.
(check this in PDF content)
12
Chicoine LG, Paffet ML, Young TL, et al. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2004; (287): 60–68.
(check this in PDF content)
13
Crombez EA, Cederbaum SD. Hyperargininemia due to liver arginase deficiency. Mol Genet Metabol. 2005; (84): 243–51.
(check this in PDF content)
14
Demougeot C, Prigent-Tesssier A, Marie C., et al Arginase inhibition reduced endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. J Hypertens. 2005; (23): 971–8.
(check this in PDF content)
15
Drexler H., Zeiher M., Meinzer K. Correction of endothelial dysfunction in coronary microcirculation of hypercholestrolemic patients by L-arginine. Lancet 1991; (67): 1301–08.
(check this in PDF content)
16
Durante W, Johnson FK, Johnson RA, et al. Arginase induces endothelial dysfunction and hypertension in obese Zucker rats. Diabetes 2005; (54): 120–124.
(check this in PDF content)
17
Hein TW, Zhang C, Wang W. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J. 2003; (17): 2328–30.
(check this in PDF content)
18
Ignarro LJ, Buga GM, Wei LH. Role of arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 2001; (98): 4202–08.
(check this in PDF content)
19
Iyer RK, Yoo PK, Kern RM, et al. Mouse model for human arginase deficiency. Mol Cell Biol 2002; (22): 4491–98.
(check this in PDF content)
20
John S, Schmeider RE. Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. Curr Hypertens Rep. 2003; (5): 199–207.
(check this in PDF content)
21
Johnson FK, Johnson RA, Peyton KJ, et al. Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2005; (288): 1057–62.
(check this in PDF content)
22
Jung AS, Wilson RM, Houser SR, et al. Modulation of contractility by myocytederived arginase in normal and hypertrophied feline myocardium. Am J Physiol Heart Circ Physiol. 2005; (34): 298–305.
(check this in PDF content)
23
Kampfer H, Pfeilschifter J, Frank S. Expression and activity of arginase isozymes during normal and diabetic-impaired skin repair. J Invest Dermatol. 2003; (121):1544–51.
(check this in PDF content)
24
Kawamoto S, Amaya Y, Murakami K, et al. Complete nucleotide sequence of cDNA and deduced amino acid sequence of the rat liver arginase. Amaya J Biol Chem. 1987; (262): 6280–83.
(check this in PDF content)
25
Lefer A, Lefer DJ. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischemia-reperfusion. Cardiovas Res. 1996; (32): 743–51.
(check this in PDF content)
26
Li H, Meininger CJ, Hawker JR, et al . Regulatory role of arginase I and II in nitric oxide, polyamine, and proline synthesis in endothelial cells. Am J Physiol Endocrinol Metab. 2001; (280): 75–82.
(check this in PDF content)
27
Loscalzo J. An experiment in nature: genetic L-arginine deficiency and NO insufficiency. J Clin Invest. 2001; (108): 663–64.
(check this in PDF content)
28
Loyaga-Rendon R, Sakamoto S, Beppu M, et al. Accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, attenuated dimethylarginine dimethylaminohydrolase activity and intimal hyperplasia in premenopausal human uterine arteries. Atherosclerosis. 2005; (178): 231–39.
(check this in PDF content)
29
Meurs H, Maarsingh H, Zaagsma J. Arginase and asthma: novel insights into nitric oxide homeostasis and airway hyperresponsiveness. TIPS 2003; (24): 450–54.
(check this in PDF content)
30
Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and limited substrate availability in sickle cell disease. JAMA 2005; (294): 81–90.
(check this in PDF content)
31
Morris SM, Bhamidipati D, Kepka-Lenhart D. Human type II arginase: sequence analysis and tissue-specific expression Gene. Mol Genet Metabol. 1997; (193): 157–61.
(check this in PDF content)
32
Shi O, Morris MS, Zoghbi H, et al. Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene. Mol Cell Biol. 2001; (21): 811–13. modeling. Scientific statements of Belgorod State University 2006; 3(23): 43–51 (in Russian). 6. Pokrovsky MV, Pokrovskaya TG, Kochkarov VI, Artushkova EB. Endothelial protective effects of L-arginine in experimental modeling of nitric oxide deficit. Experimental and clinical pharmacology 2008; 71(2): 29–31 (in Russian). 7. Solonin DL, Syrensky AV, Galagudza MM, et al. The role of nitric oxide in the regulation of arterial distensibility vessels in normal and hypertensive rats. Artherial hypertension 2002; (6): 57–64 (in Russian). 8. Tsepeleva SA, Pokrovsky MV, Pokrov
(check this in PDF content)
33
Teupser D, Burkhardt DR, Wilfert W, Haffner I, et al. Identification of Federal State Autonomous Educational Institution of Higher Professional Education Belgorod National Research University «Belgorod State University», 85 Pobedy street, Belgorod, 308015, Russian Federation. Yakushev VI. Postgraduate student of pharmacological department. Pokrovsky MV. Chief of the pharmacological department. Doctor of Medical Sciences.. Beskhmelnitsyna EA. Postgraduate student of pharmacological department. Myasishcheva OV. Postgraduate student of pharmacological department. Litvinova AS. Student. Krivoshapova II. Student. Demchenko SA. Postgraduate student of pharmacological department. Федеральное государственное автономное образовательное учреждение
(check this in PDF content)
34
Tousoulis D, Antoniades C, Tentolouris C. L-Arginine in cardiovascular disease: dream or reality? Vasc Med. 2002; (7): 203–11.
(check this in PDF content)
35
Vockley JG, Jenkinson CP, Shukla H, et al. Cloning and characterization of the human type II arginase gene. Vockley 1996; (2): 118–23.
(check this in PDF content)
36
White AR, Ryoo S, Li D, et al. Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension 2007; (19): 57–62.
(check this in PDF content)
37
Xu W, Kaneko T, Zheng S, et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary artery hypertension. FASEB J. 2004; (18): 1746–1748.
(check this in PDF content)
38
Zhang C, Hein TW, Wang W, et al. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J. 2001; (15): 1264–66. macrophage arginase I as a new candidate gene of atherosclerosis resistance. Arterioscler Thromb Vasc Biol. 2006; (26): 365–71.
(check this in PDF content)